COSMOS Pharmaceutical Corporation (3349) Price & Analysis

Compare

1 Followers

3349 Stock Chart & Stats

¥7643.00

¥109.00(1.60%)

At close: Jan 08 4:00 PM EST

¥7643.00

¥109.00(1.60%)

Day’s Range― - ―

52-Week Range¥6,672.00 - ¥10,045.00

Previous CloseN/A

Volume659.40K

Average Volume (3M)399.89K

Market Cap

¥620.88B

Enterprise Value¥696.92B

Total Cash (Recent Filing)¥57.04B

Total Debt (Recent Filing)¥49.96B

Price to Earnings (P/E)19.9

Beta-0.22

Next Earnings

Jul 10, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.93%

Share Statistics

EPS (TTM)103.10

Shares Outstanding80,001,600

10 Day Avg. Volume586,980

30 Day Avg. Volume399,893

Financial Highlights & Ratios

PEG Ratio0.85

Price to Book (P/B)2.72

Price to Sales (P/S)0.69

P/FCF Ratio-814.90

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥9,500.00

Price Target Upside24.30% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

COSMOS Pharmaceutical Corporation News

Upgraded to Buy: COSMOS Pharmaceutical’s Attractive Valuation and Growth Potential

In a report released on December 14, Sho Kawano from Goldman Sachs upgraded COSMOS Pharmaceutical Corporation to a...

24d ago

COSMOS Pharmaceutical Reports Modest Growth in Q3 2025 Financial Results

COSMOS Pharmaceutical Corporation ( ($JP:3349) ) has provided an announcement. COSMOS Pharmaceutical Corporation reported its consolidated financial results...

3M ago

3349

COSMOS Pharmaceutical Considers Lowering Investment Unit to Boost Market Activity

COSMOS Pharmaceutical Corporation ( ($JP:3349) ) has shared an update. COSMOS Pharmaceutical Corporation is considering lowering its investment...

5M ago

3349

COSMOS Pharmaceutical Announces Board of Directors Changes

COSMOS Pharmaceutical Corporation ( ($JP:3349) ) has issued an update. COSMOS Pharmaceutical Corporation has announced changes in its...

6M ago

3349

COSMOS Pharmaceutical Increases Year-End Dividend Following Stock Split

An announcement from COSMOS Pharmaceutical Corporation ( ($JP:3349) ) is now available. COSMOS Pharmaceutical Corporation announced an increase...

6M ago

3349

COSMOS Pharmaceutical Reports Strong Financial Growth for Fiscal Year 2025

COSMOS Pharmaceutical Corporation ( ($JP:3349) ) has provided an announcement. COSMOS Pharmaceutical Corporation reported a significant increase in...

6M ago

3349

COSMOS Pharmaceutical Reports Strong Financial Growth for Nine-Month Period

The latest announcement is out from COSMOS Pharmaceutical Corporation ( ($JP:3349) ). COSMOS Pharmaceutical Corporation reported a significant...

9M ago

3349

COSMOS Pharmaceutical Reports Strong Growth and Strategic Stock Split

The latest announcement is out from COSMOS Pharmaceutical Corporation ( ($JP:3349) ). COSMOS Pharmaceutical Corporation reported strong financial...

12M ago

3349

COSMOS Pharmaceutical Posts Strong Q1 Growth

COSMOS Pharmaceutical Corporation (JP:3349) has released an update. COSMOS Pharmaceutical Corporation reported a strong start to the fiscal...

1y ago

3349

Cosmos Pharma Reports Growth and Plans Stock Split

COSMOS Pharmaceutical Corporation (JP:3349) has released an update. Cosmos Pharmaceutical Corporation reported an increase in net sales to...

1y ago

3349

3349 FAQ

What was COSMOS Pharmaceutical Corporation’s price range in the past 12 months?

COSMOS Pharmaceutical Corporation lowest stock price was ¥6672.00 and its highest was ¥10045.00 in the past 12 months.

What is COSMOS Pharmaceutical Corporation’s market cap?

COSMOS Pharmaceutical Corporation’s market cap is ¥620.88B.

When is COSMOS Pharmaceutical Corporation’s upcoming earnings report date?

COSMOS Pharmaceutical Corporation’s upcoming earnings report date is Jul 10, 2026 which is in 182 days.

How were COSMOS Pharmaceutical Corporation’s earnings last quarter?

COSMOS Pharmaceutical Corporation released its earnings results on Oct 08, 2025. The company reported ¥103.1 earnings per share for the quarter, missing the consensus estimate of ¥112.021 by -¥8.921.

Is COSMOS Pharmaceutical Corporation overvalued?

According to Wall Street analysts COSMOS Pharmaceutical Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does COSMOS Pharmaceutical Corporation pay dividends?

COSMOS Pharmaceutical Corporation pays a Semiannually dividend of ¥37.5 which represents an annual dividend yield of 0.93%. See more information on COSMOS Pharmaceutical Corporation dividends here

What is COSMOS Pharmaceutical Corporation’s EPS estimate?

COSMOS Pharmaceutical Corporation’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does COSMOS Pharmaceutical Corporation have?

COSMOS Pharmaceutical Corporation has 80,001,600 shares outstanding.

What happened to COSMOS Pharmaceutical Corporation’s price movement after its last earnings report?

COSMOS Pharmaceutical Corporation reported an EPS of ¥103.1 in its last earnings report, missing expectations of ¥112.021. Following the earnings report the stock price went up 0.925%.

Which hedge fund is a major shareholder of COSMOS Pharmaceutical Corporation?

Currently, no hedge funds are holding shares in JP:3349

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

COSMOS Pharmaceutical Corporation

COSMOS Pharmaceutical Corporation (3349) is a prominent player in the Japanese pharmaceutical industry, specializing in the manufacture and distribution of a wide range of healthcare products. The company operates primarily in the over-the-counter (OTC) drug sector, providing consumers with accessible health solutions that include pain relievers, cold remedies, and dietary supplements. In addition to OTC medications, COSMOS also engages in the development of prescription drugs and health-related products, aiming to enhance the quality of life for its customers.

COSMOS Pharmaceutical Corporation (3349) Earnings & Revenues

Historic Earnings Reports

3349 Stock 12 Month Forecast

Average Price Target

¥9,500.00

▲(24.30% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6635":"¥6,635","8068":"¥8,068","9501":"¥9,501","7351.5":"¥7,351.5","8784.5":"¥8,784.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥10K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6635,7351.5,8068,8784.5,9501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7943,8062.7692307692305,8182.538461538462,8302.307692307691,8422.076923076924,8541.846153846154,8661.615384615385,8781.384615384615,8901.153846153846,9020.923076923076,9140.692307692309,9260.461538461539,9380.23076923077,{"y":9500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7943,8062.7692307692305,8182.538461538462,8302.307692307691,8422.076923076924,8541.846153846154,8661.615384615385,8781.384615384615,8901.153846153846,9020.923076923076,9140.692307692309,9260.461538461539,9380.23076923077,{"y":9500,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7943,8062.7692307692305,8182.538461538462,8302.307692307691,8422.076923076924,8541.846153846154,8661.615384615385,8781.384615384615,8901.153846153846,9020.923076923076,9140.692307692309,9260.461538461539,9380.23076923077,{"y":9500,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6636,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7194.87,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6978.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7428.72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9136.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8921.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9119.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9495.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8770.24,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8474.72,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6864.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7450,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7943,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >